A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)
Status:
Completed
Trial end date:
2019-09-26
Target enrollment:
Participant gender:
Summary
This study will evaluate the anti-retroviral activity of MK-8527 in HIV-1 infected, ART-naïve
participants. The primary hypothesis is that MK-8527 has superior anti-retroviral activity
compared to placebo, as measured by change from baseline in plasma HIV-1 ribonucleic acid
(RNA) at 168 hours postdose.